CN101843668A - Chinese medicinal granules for treating femoral head necrosis and preparation method thereof - Google Patents

Chinese medicinal granules for treating femoral head necrosis and preparation method thereof Download PDF

Info

Publication number
CN101843668A
CN101843668A CN 201010161388 CN201010161388A CN101843668A CN 101843668 A CN101843668 A CN 101843668A CN 201010161388 CN201010161388 CN 201010161388 CN 201010161388 A CN201010161388 A CN 201010161388A CN 101843668 A CN101843668 A CN 101843668A
Authority
CN
China
Prior art keywords
ethanol
head necrosis
adjuvant
parts
chinese medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 201010161388
Other languages
Chinese (zh)
Other versions
CN101843668B (en
Inventor
尹华
章建华
肖鲁伟
童培健
李昌煜
石森林
邹莉
董晓烨
张春霞
王知青
李雯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Chinese Medicine University ZCMU
Original Assignee
Zhejiang Chinese Medicine University ZCMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Chinese Medicine University ZCMU filed Critical Zhejiang Chinese Medicine University ZCMU
Priority to CN 201010161388 priority Critical patent/CN101843668B/en
Publication of CN101843668A publication Critical patent/CN101843668A/en
Application granted granted Critical
Publication of CN101843668B publication Critical patent/CN101843668B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides Chinese medicinal granules for treating femoral head necrosis and a preparation method thereof. The Chinese medicinal granules comprise the following raw materials in part by weight: 1,000 to 1,200 parts of astragalus, 1,000 to 1,200 parts of root of red-rooted salvia, 500 to 600 parts of eucommia bark, 1,000 to 1,200 parts of Chinese angelica, 1,000 to 1,200 parts of rhizoma corydalis and 350 to 400 parts of south dodder seed. The Chinese medicinal granules have the effects of tonifying liver and kidney, benefiting vital energy and activating blood, and freeing network vessels and relieving pain, is clinically used for treating ischemic femoral head necrosis at early and middle stages. The Chinese medicinal granules have the characteristics of low hygroscopicity, portability, convenient use, stable quality, small dosage of auxiliary materials and the like. Added flavoring agent can improve mouthfeel of medicaments, and the Chinese medicinal granules are the sugar-free granules, and are convenient for patients (comprising middle and old aged patients with diabetes and obesity) to take for a long time.

Description

A kind of Chinese medicine granules for the treatment of femur head necrosis and preparation method thereof
(1) technical field: the present invention relates to a kind of Chinese medicine (the strong bone of stilbene ginseng) granule for the treatment of femur head necrosis and preparation method thereof, belong to technical field of traditional Chinese medicine pharmacy.
(2) background technology: femur head necrosis (Osteonecrosis of the Femoral Head, ONFH) be meant owing to reasons such as life-time service hormone, wound, excessive drinking, fatty livers, thereby cause not enough a kind of orthopaedics commonly encountered diseases and the difficult disease that causes ischemic necrosis of femoral head blood supply, the long disability rate height of its course of disease, femur head necrosis is divided into traumatic femur head necrosis and atraumatic femur head necrosis two big classes clinically, and is wherein the most common with atraumatic femur head necrosis (hormone, ethanol etc. cause).Since the 1950's, along with hormone medicine in clinical extensive use, increase progressively fast by the corticosteroid femur head necrosis due to the hormone, become the first place of the femur head necrosis cause of disease, the femur head necrosis sickness rate rises gradually in recent years, and age of onset has downward trend gradually.The main clinical manifestation of femur head necrosis is hip pain, limping, joint function disturbance, then be further development of collapse of the femoral head, distortion, osteoarthritis, finally cause the joint maimed person, cause patient's lifelong disability, have a strong impact on normal work of patient and life, all caused great burden in spirit and economically for patient and family thereof.At present, the Therapeutic Method of femur head necrosis has Drug therapy, interventional therapy, core decompression art, bone grafting, total hip replacement etc.Usually the total hip replacement operation of adopting clinically, though success rate is higher, but costly (2~50,000/people), and the average life of artificial hip joint has only 10~15 years, need to regularly replace, metathetical hip joint also may produce complication such as infection, loosening, dislocation, has caused the anaphase effect of operation not ideal enough.And other operative treatments alleviating pain within a certain period of time only, but the process that can not stop course of disease development, worsen.Drug therapy does not still have ideal chemicals so far, and the medicine of clinical practice at present mainly contains fat-reducing medicament, anticoagulant, cell regulating factor, only alleviates, improves symptom, but can not effect a radical cure.In sum, do not find specific medicament and method as yet for the treatment of femur head necrosis both at home and abroad, therefore, the method and the medicine of the anti-treating caput femoris necrosis of research and development have important clinic value and realistic meaning, states such as Japan, the U.S. all classify this disease as unsolved refractory disease, drop into huge fund and carry out the research and development of medicine.
The traditional Chinese medical science is thought, femur head necrosis belongs to " rheumatism involving the bone ", " osteomyelitis ", treatment to primary disease is the basic rule of treatment with " liver and kidney tonifying, blood circulation promoting and blood stasis dispelling, regulating QI to relieve pain ", emphasize blood circulation promoting and blood stasis dispelling in early days, later stage is paid attention to invigorating the kidney and strengthening the bones, by improving capital blood microcirculation, suppress capillary permeability, promote osteoblastic propagation, reduce intra-osteal pressure, progressively recovering capital normal physiological function, thereby reach the purpose for the treatment of both the principal and secondary aspects of a disease.But the preparation that authentication code is arranged at present only has red strongly fragrant bone health ball, living arteries and veins to become capsule, clinical most employing is from intending compound preparation, as: strong bone blood activating decoction, the bone soup of living, bone bring back to life soup etc., though these prescriptions to early, mid-term femur head necrosis have prevention and therapeutical effect, but be limited to the experimental stage mostly, exist in clinical use that dosage form is backward, quality is uncontrollable, curative effect is unstable, take problems such as inconvenience and application limit.At present, the medicine that does not still have specific anti-treating caput femoris necrosis both at home and abroad.Based on the advantages such as toxic and side effects of Chinese medicine primary disease determined curative effect, no wound, no chemicals, from Chinese medicine and natural drug, seek and exploitation has independent intellectual property right, new Chinese medicine safe and effective, treatment femur head necrosis that technology is advanced, stable and controllable for quality has become the emphasis of research and development.
(3) summary of the invention: task of the present invention provides a kind of Chinese medicine granules of effective treatment femur head necrosis; Another task of the present invention provides the preparation method of this Chinese medicine granules, and this method can big limit be extracted the material medicine effective ingredient, improves drug effect.
The present invention is made up of raw material of Chinese medicine such as the Radix Astragali, Radix Salviae Miltiorrhizae, the Cortex Eucommiae, Radix Angelicae Sinensis, Semen Cuscutae, Rhizoma Corydalis, reuses the invigorating middle warmer of Radix Astragali QI invigorating in the side, gets the reason of QI and blood interpromoting relation in five elements interaction, and QI invigorating stagnates so that hemopoietic is capable, is monarch drug; The Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, Cortex Eucommiae invigorating the kidney and strengthening the bones is ministerial drug; Assistant is with Radix Angelicae Sinensis nourishing blood and promoting blood circulation, removing obstruction in the collateral to relieve pain, the Semen Cuscutae liver and kidney tonifying; The Rhizoma Corydalis blood-activating and qi-promoting, through sick institute, blood stasis dispelling is with pain relieving.All medicines share, and play the effect of vital energy benefiting and the kidney invigorating, blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain altogether.
The present invention treats Chinese medicine (the strong bone of the stilbene ginseng) granular preparation of femur head necrosis, and each crude drug weight ratio is: Radix Astragali 1000-1200, Radix Salviae Miltiorrhizae 1000-1200, Cortex Eucommiae 500-600, Radix Angelicae Sinensis 1000-1200, Rhizoma Corydalis 1000-1200, Semen Cuscutae 350-400.
Each crude drug of this Chinese medicine (the strong bone of stilbene ginseng) granular preparation most preferably weight proportion is: the Radix Astragali 1100, Radix Salviae Miltiorrhizae 1100, the Cortex Eucommiae 550, Radix Angelicae Sinensis 1100, Rhizoma Corydalis 1100, Semen Cuscutae 370.
The preparation method of Chinese medicine of the present invention (the strong bone of stilbene ginseng) granular preparation comprises the steps:
1. material choice
Decoction pieces such as the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Rhizoma Corydalis in the prescription are carried out thin layer differentiate (TLC) and HPLC assay, " what require under Chinese pharmacopoeia (an one) the medical material item is qualified decoction pieces, feeds intake to meet 2005 editions;
2, extraction process
Each crude drug mixing was steeped 0.5-2 hour with 6-15 times of water logging, extracts 1-4 time, and each 0.5-2 hour, filter, merging filtrate, being evaporated to relative density is 1.05~1.10 (reduce to and detect the relative density value under the room temperature condition, be generally 20-25 ℃, be as follows);
3, purifying process (precipitate with ethanol)
To the extracting solution that step 2 obtains, add 95% ethanol and make and contain the alcohol amount and be 50-70%, precipitate with ethanol 6-24h reclaims ethanol to there not being the alcohol flavor, and to be evaporated to relative density of medicine liquid be 1.05~1.15;
4, drying process
Medicinal liquid to step 3 obtains is heated to 60 ℃, adds the 1-5% dextrin, and at intake air temperature 140-180 ℃, 70-90 ℃ of air outlet temperature, charging rate are to carry out spray drying under the 40kg/h condition, obtain dry extract;
The spray drying optimal conditions: intake air temperature is that 160 ℃, 80 ℃ of air outlet temperature, charging rate are 40kg/h;
5, moulding process
The dry extract that step 4 is obtained mixes with adjuvant, the mixed proportion of dry extract and adjuvant is 1: 1-4: 1, with 85-95% ethanol is wetting agent, 30% wetting agent and the 1-2% steviosin that add adjuvant and extractum total amount are made soft material, crossing 10 mesh sieves granulates, 55 ℃ of oven dry, granulate, packing gets product.Adjuvant of the present invention is the compound of dextrin and lactose, and its weight ratio is 2: 1.
In product research, the applicant finds, has problems such as patients such as carrying after inconvenience, perishable, the sugaring diabetes should not take if make oral liquid, and its suitable colony is reduced, and clinical use is influenced.So the present invention is made into granule, have carry, taking convenience, help divided dose, steady quality; And add steviosin as correctives, not only improved mouthfeel, and enlarged suitable colony.For this reason, the applicant has carried out the The effects of system to preparation technology of the present invention, the rate of transform with the effective ingredient salvianolic acid B of the effective ingredient astragaloside of the monarch drug Radix Astragali in the side, ministerial drug Radix Salviae Miltiorrhizae is an evaluation index, investigate the influence of medical material granularity, soak time, amount of water, extraction time and extraction time by single factor experiment and orthogonal test, (weight coefficient is an astragaloside: salvianolic acid B=0.6: 0.4) to adopt the aggregative weighted point system, determine the optimum extraction process of the strong osseous granules of stilbene ginseng, and optimised process is carried out 3 batches of demonstration tests.Investigate the influence of concentration of alcohol, relative density of medicine liquid, precipitate with ethanol time, determine best purifying process purifying process; Compare spray drying, microwave drying and three kinds of drying meanss of drying under reduced pressure, determine to adopt spray drying method, to get powder rate, the index components rate of transform and appearance character is evaluation index, further investigate the influence of factors such as medicinal liquid density, intake air temperature, air outlet temperature, charging rate and dextrin consumption, determine the spray drying optimal processing parameter; In Study on Forming, the factors such as ratio, wetting agent and correctives so that single factor experiment screens proportioning, adjuvant and the extract powder of each single adjuvant, different auxiliary material composition mixed accessories on the basis of single factor experiment, adopt L 9(3 4) orthogonal test investigates adjuvant and the ratio of extractum, the concentration and the consumption of wetting agent, with ratio of briquetting, dissolubility, angle of repose, granulation complexity and mouthfeel etc. is evaluation index, determine the molding technological condition of the strong osseous granules of stilbene ginseng, and according to determined preparation technology, produce test agent in 3 batches of strong osseous granuleses of stilbene ginseng, carry out quality standard and preliminarily stabilised Journal of Sex Research.
For this reason, the applicant selects to have carried out relevant experimental study with adjuvant to the preparation technology of preparation of the present invention, and is specific as follows:
Test 1: extraction process is investigated
The applicant finds in the product research process, and the amount of water of preparation of the present invention, extraction time, extraction time influence extraction ratio of effective constituents, so extraction conditions is investigated.
1, adopts orthogonal test to carry out preferably, investigate the influence of amount of water, extraction time and extraction time, by 4 factors, 3 horizontal L 9(3 4) table carries out orthogonal test.
Extraction process factor level table
Figure GSA00000086514300041
Get prescription ratio medical material, under the operation repetitive condition, press L respectively 9(3 4) 9 experimental conditions arranging of orthogonal table carry out, the rate of transform with the effective ingredient salvianolic acid B of the effective ingredient astragaloside of the monarch drug Radix Astragali under each factor level, ministerial drug Radix Salviae Miltiorrhizae is an evaluation index, (weight coefficient is an astragaloside: the optimum extraction process of salvianolic acid B=0.6: 0.4) determining the strong osseous granules of stilbene ginseng with the aggregative weighted point system, carry out variance analysis, consider in conjunction with big production practical situation and energy consumption, draw optimum extraction process.
2, test method
Take by weighing technology under the recipe quantity and investigate 9 parts of the decoction pieces of consumption, every part of 145g soaks 1.0h, by above-mentioned EXPERIMENTAL DESIGN, tests, and investigates the influence of amount of water, extraction time, extraction time, determines optimum extraction process.
Extraction process L 9(3 4) orthogonal experiments
Figure GSA00000086514300051
Extraction process L 9(3 4) orthogonal experiment plan takes into account statistical disposition
Variance analysis
Figure GSA00000086514300053
F 0.05(2,2)=19;F 0.01,(2,2)=99
Intuitive analysis shows that each factor effect primary and secondary is C (extraction time)>A (amount of water)>B (extraction time), i.e. extraction time influence is the most remarkable, secondly is amount of water, and the extraction time influence is minimum, and optimum extraction process is C 3A 3B 3Variance analysis shows that extraction time has the significance influence, and amount of water and extraction time do not have statistically-significant difference.Because of B 1And B 3Differ very little, consider that from big production practical situation and energy consumption the best extraction process by water of determining is C 3A 3B 1,, extract 3 times each 0.5h promptly with 12 times of water yields.Said extracted liquid is evaporated to relative density 1.05-1.10, carries out purification.
Test 2: purifying process is investigated
1, orthogonal test is preferred, adopts ethanol precipitation, investigates the influence of concentration of alcohol (containing the alcohol amount), precipitate with ethanol time and medicinal liquid density, by 4 factors, 3 horizontal L 9(3 4) table carries out orthogonal test.
Purifying process factor level table
Figure GSA00000086514300061
Get prescription ratio medical material, under the operation repetitive condition, extract, extracting solution is equally divided into 9 parts, press L respectively by the optimum extraction process condition of determining 9(3 4) 9 experimental conditions arranging of orthogonal table carry out, and are evaluation index with the rate of transform of astragaloside, salvianolic acid B under each factor level, with reference to yield of extract, the result are analyzed, and determine best purifying process.
2, test method
Take by weighing technology under the recipe quantity and investigate 9 parts of the decoction pieces of consumption, be total to 1305g, (that is: decoction pieces adds 12 times of water gagings, soaks 1h by the optimum extraction process extraction of determining, reflux, extract, 3 times, each 0.5h), extracting solution is equally divided into 9 parts, is evaporated to certain density respectively, adopt above-mentioned EXPERIMENTAL DESIGN, test, investigate the influence of concentration of alcohol (containing the alcohol amount), precipitate with ethanol time and medicinal liquid density, determine best purifying process.
Purifying process L 9(3 4) orthogonal experiments
Purifying process L 9(3 4) orthogonal experiment plan takes into account statistical disposition
Variance analysis
Figure GSA00000086514300073
F 0.05,(2,2)=19;F 0.01,(2,2)=99
Intuitive analysis shows that the effect primary and secondary of each factor is C (medicinal liquid density)>A (concentration of alcohol)>B (precipitate with ethanol time), i.e. relative density of medicine liquid influence is the most remarkable, secondly is concentration of alcohol (containing the alcohol amount), precipitate with ethanol time effects minimum.Variance analysis shows that factor C (medicinal liquid density) has significant difference, factor A (precipitate with ethanol time) and factor B (relative density of medicine liquid) there was no significant difference; Determine that best purifying process is C 1A 1B 3, promptly being evaporated to relative density of medicine liquid is 1.05~1.10, adds 95% ethanol and makes that to contain alcohol amount be 50%, precipitate with ethanol 24h.The medicinal liquid of purification gained reclaims ethanol to there not being the alcohol flavor, and to be evaporated to relative density of medicine liquid be 1.05~1.15, carries out spray drying.
Test 3: moulding process
The selection of suitable excipients is to make the particulate key of high-quality, should take into full account the influence of adjuvant to preparation, comprise mouldability, hygroscopicity and stability etc., adjuvant should be a principle with having no adverse effects with minimum application quantity, and consideration cost, fully satisfying the preparation process requirement, guaranteeing under the product quality premise consumption of adjuvant to be minimized.The present invention finds that the hydroscopicity and the ratio of briquetting of lactose and dextrin obviously is better than starch and carboxymethyl starch sodium when investigating supplementary product kind; The ratio of briquetting of lactose is better than dextrin, but the too late dextrin of hydroscopicity, and easily liquefaction after the lactose moisture absorption, particle adhesion, moreover the lactose price is higher.Therefore, single adjuvant can not solve problems such as molding particles rate, hydroscopicity, melting fully, form mixed accessories so select lactose and dextrin to mix, further investigate its influence, determine the composition of best mixed accessories grain forming rate, hydroscopicity and melting according to different proportion.
1, screens the factors such as ratio, wetting agent and correctives of proportioning, adjuvant and the extract powder of each single adjuvant, different auxiliary material composition mixed accessories with single factor experiment; On the basis of single factor experiment, adopt orthogonal test preferred, investigate the adjuvant and the ratio of extractum, the concentration and the consumption of wetting agent, by 4 factors, 3 horizontal L 9(3 4) table carries out orthogonal test.
Moulding process factor level table
Figure GSA00000086514300081
With ratio of briquetting, dissolubility, angle of repose, granulation complexity and mouthfeel etc. is evaluation index, determines the molding technological condition of the strong osseous granules of stilbene ginseng.
2, test method
With ethanol is wetting agent, adopts L 9(3 4) orthogonal test carries out the optimization of molding technological condition, investigates the extractum and the ratio of adjuvant, the concentration and the consumption of wetting agent, its ratio of briquetting, granulation situation and melting are investigated.
Moulding process L 9(3 4) orthogonal experiments
Figure GSA00000086514300091
The ratio of briquetting variance analysis
Figure GSA00000086514300092
F 0.05,(2,2)=19;F 0.01,(2,2)=99
Orthogonal test granulation situation and melting result
Figure GSA00000086514300093
Figure GSA00000086514300101
From intuitive analysis, the ratio of extractum and adjuvant, the concentration of wetting agent and consumption are remarkable to the ratio of briquetting influence, and influence is A>B>C in proper order, the scale effect that is extractum and adjuvant is the most remarkable, next is the concentration of wetting agent, and the consumption influence of wetting agent is minimum, and best moulding process is A 2B 3C 3The results of analysis of variance shows, there were significant differences to the influence of the ratio of briquetting of moulding process for the ratio of extractum and adjuvant and the concentration of wetting agent, so definite best moulding process is A 2B 3C 3, promptly the ratio of extractum and adjuvant is 4: 1, and the wetting agent concentration of ethanol is 90%, and consumption is 30%.
By system experimentation research, determine that the best preparation technology of the strong osseous granules of stilbene ginseng is: decoction pieces soaks 1h, extracts 3 times with 12 times of water yields, each 0.5h; Extracting solution is evaporated to relative density 1.05-1.10, and adding 95% ethanol is 50% to containing the alcohol amount, precipitate with ethanol 24h, and reclaiming ethanol to relative density of medicine liquid is 1.10; Heating medicinal liquid to 60 ℃ adds 2.5% dextrin, is that 160 ℃, 80 ℃ of air outlet temperature, charging rate are to carry out spray drying under the 40kg/h condition at intake air temperature; (dextrin: lactose=2: 1) be 4: 1 mixed, add 1% steviosin, be wetting agent with 90% ethanol to dried extract powder according to extractum and adjuvant, the wetting agent that adds adjuvant and extractum total amount 30% is made soft material, crosses 10 mesh sieves and granulates 55 ℃ of oven dry, granulate, packing are promptly.
The strong bone granule of stilbene ginseng of the present invention preparation is tan granule, feeble QI perfume (or spice), and it is sweet distinguish the flavor of, and little hardship has the effect of liver and kidney tonifying, benefiting QI for activating blood circulation, removing obstruction in the collateral to relieve pain, clinical morning, the mid-term ischemia femur head necrosis that is used for the treatment of.
Pharmacodynamic experiment is the result show: the strong bone granule of stilbene ginseng can make bone trabecula, osteocyte and medullary cavity structure, the form of femur head necrosis rat improve; Can reduce medullary cavity fat cell hypertrophy hypertrophy, outgrowth lesion degree; Can improve unusual hemorheology and dyslipidemia and increase state, improve bone density value, increase the intensity of osseous tissue, improve the biomechanical property of osseous tissue, corticosteroid femur head necrosis is had therapeutical effect preferably.Show that the strong osseous granules preparation technology of determined stilbene ginseng is reasonable, can extract the active ingredient of medicine more completely, guarantee drug effect.
(4) specific embodiments:
Come by the following examples further to set forth the present invention, should be noted that, these embodiment only are the preferred example in the invention process, do not constitute any restriction to the scope of the invention.
Embodiment 1:
Crude drug is formed: Radix Astragali 1100g, Radix Salviae Miltiorrhizae 1100g, Cortex Eucommiae 550g, Radix Angelicae Sinensis 1100g, Rhizoma Corydalis 1100, Semen Cuscutae 370g;
Preparation method:
Differentiate (TLC) and HPLC content assaying method preferred feedstock medicine with thin layer, preferred raw medicinal material is soaked 1h, extract 3 times, each 0.5h with 12 times of water gaging amounts; It is 1.05~1.10 (temperature is reduced to and detected the relative density value under the room temperature condition, is generally 20-25 ℃, and is as follows) that extracting solution is evaporated to relative density, add 95% ethanol and make that to contain alcohol amount be 50%, precipitate with ethanol 24h reclaims ethanol to there not being the alcohol flavor, and to be evaporated to relative density of medicine liquid be 1.10; Heating medicinal liquid to 60 ℃ adds 2.5% dextrin, and 160 ℃ of intake air temperatures, 80 ℃ of air outlet temperature, charging rate are to carry out spray drying under the 40kg/h condition, obtain dry extract; According to dry extract and adjuvant (2: 1 mixed accessories of dextrin-lactose) is 4: 1 mixed, is wetting agent with 90% ethanol, and the wetting agent and 1% steviosin that add adjuvant and extractum total amount 30% are made soft material, crossing 10 mesh sieves granulates, 55 ℃ of oven dry, granulate, packing promptly gets the strong osseous granules of stilbene ginseng.
Embodiment 2:
Crude drug is formed: Radix Astragali 1000g, Radix Salviae Miltiorrhizae 1000g, Cortex Eucommiae 500g, Radix Angelicae Sinensis 1000g, Rhizoma Corydalis 1000g, Semen Cuscutae 350g;
Preparation method: differentiate (TLC) and HPLC content assaying method preferred feedstock medicine with thin layer, preferred raw medicinal material is soaked 0.5h, extract 2 times, each 1h with 8 times of water gaging amounts; It is 1.05~1.10 that extracting solution is evaporated to relative density, adds 95% ethanol and makes that to contain alcohol amount be 60%, and precipitate with ethanol 6h reclaims ethanol to there not being the alcohol flavor, and to be evaporated to relative density of medicine liquid be 1.10; Heating medicinal liquid to 60 ℃ adds 2% dextrin, and 180 ℃ of intake air temperatures, 90 ℃ of air outlet temperature, charging rate are to carry out spray drying under the 40kg/h condition, obtain dry extract; It according to dry extract and adjuvant (2: 1 mixed accessories of dextrin-lactose) 1.5: 1 mixed, with 85% ethanol is wetting agent, the wetting agent and 2% steviosin that add adjuvant and extractum total amount 30% are made soft material, crossing 10 mesh sieves granulates, 55 ℃ of oven dry, granulate, packing promptly get the strong osseous granules of stilbene ginseng.
Embodiment 3:
Crude drug is formed: Radix Astragali 1200g, Radix Salviae Miltiorrhizae 1200g, Cortex Eucommiae 600g, Radix Angelicae Sinensis 1200g, Rhizoma Corydalis 1200, Semen Cuscutae 400g;
Preparation method: differentiate (TLC) and HPLC content assaying method preferred feedstock medicine with thin layer, preferred raw medicinal material is soaked 2h, extract 3 times, each 1h with 12 times of water gaging amounts; It is 1.05~1.10 that extracting solution is evaporated to relative density, adds 95% ethanol and makes that to contain alcohol amount be 50%, and precipitate with ethanol 12h reclaims ethanol to there not being the alcohol flavor, and to be evaporated to relative density of medicine liquid be 1.10; Heating medicinal liquid to 60 ℃ adds 3% dextrin, and 160 ℃ of intake air temperatures, 80 ℃ of air outlet temperature, charging rate are to carry out spray drying under the 40kg/h condition, obtain dry extract; According to dry extract and adjuvant (2: 1 mixed accessories of dextrin-lactose) is 3: 1 mixed, is wetting agent with 90% ethanol, and the wetting agent and 1% steviosin that add adjuvant and extractum total amount 30% are made soft material, crossing 10 mesh sieves granulates, 55 ℃ of oven dry, granulate, packing promptly gets the strong osseous granules of stilbene ginseng.

Claims (4)

1. Chinese medicine granules for the treatment of femur head necrosis, its crude drug consists of the Radix Astragali, Radix Salviae Miltiorrhizae, the Cortex Eucommiae, Radix Angelicae Sinensis, Rhizoma Corydalis, Semen Cuscutae, each crude drug proportioning is: Radix Astragali 1000-1200, Radix Salviae Miltiorrhizae 1000-1200, Cortex Eucommiae 500-600, Radix Angelicae Sinensis 1000-1200, Rhizoma Corydalis 1000-1200, Semen Cuscutae 350-400, each above-mentioned crude drug is weight ratio.
2. according to the Chinese medicine granules of the described treatment femur head necrosis of claim 1, it is characterized in that described each crude drug proportioning is: the Radix Astragali 1100, Radix Salviae Miltiorrhizae 1100, the Cortex Eucommiae 550, Radix Angelicae Sinensis 1100, Rhizoma Corydalis 1100, Semen Cuscutae 370, each above-mentioned crude drug is weight ratio.
3. the preparation method of the Chinese medicine granules of treatment femur head necrosis according to claim 1 and 2, it is characterized in that: by proportioning crude drug is mixed, steeped 0.5-2 hour, extract 1-4 time with 6-15 times of water logging, each 0.5-2 hour, filter, merging filtrate is evaporated to that relative density is 1.05~1.10 under the room temperature condition, adding 95% ethanol makes the alcohol amount of containing be 50-70%, precipitate with ethanol 6-24h reclaims ethanol to there not being the alcohol flavor, and is evaporated to that relative density is 1.05~1.15 under the medicinal liquid room temperature condition, add the 1-5% dextrin, spray drying obtains dry extract, adds adjuvant, wetting agent and correctives, sieve, oven dry, granulate, packing promptly gets the strong bone granule of stilbene ginseng;
Wherein adjuvant is dextrin and lactose, dextrin: the lactose weight ratio is 2: 1, and dry extract and adjuvant weight ratio are 4: 1-1: 1, and correctives is a steviosin, and the consumption of correctives is the 1-2% of granule gross weight, and wetting agent is a 85-95% ethanol.
4. the preparation method of the Chinese medicine granules of treatment femur head necrosis according to claim 3 is characterized in that: each crude drug mixes, and adds 8-12 times of water gaging and soaks 1 hour, extracts each 0.5 hour 3 times; Filter, merging filtrate is evaporated to that relative density is 1.05~1.10 under the room temperature condition, and add 95% ethanol and make that to contain the alcohol amount be 50%, precipitate with ethanol 24h, reclaiming ethanol relative density to the medicinal liquid room temperature condition is 1.05~1.15; Heating medicinal liquid to 60 ℃ adding 2.5% dextrin, spray drying; Dried extract powder is 4: 1 a mixed according to the weight ratio of extractum and adjuvant, adds 1% steviosin, is wetting agent with 85-90% ethanol, the wetting agent that adds adjuvant and extractum total amount 30% is made soft material, crosses 10 mesh sieves and granulates 55 ℃ of oven dry, granulate, packing are promptly.
CN 201010161388 2010-04-28 2010-04-28 Chinese medicinal granules for treating femoral head necrosis and preparation method thereof Expired - Fee Related CN101843668B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201010161388 CN101843668B (en) 2010-04-28 2010-04-28 Chinese medicinal granules for treating femoral head necrosis and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201010161388 CN101843668B (en) 2010-04-28 2010-04-28 Chinese medicinal granules for treating femoral head necrosis and preparation method thereof

Publications (2)

Publication Number Publication Date
CN101843668A true CN101843668A (en) 2010-09-29
CN101843668B CN101843668B (en) 2012-07-04

Family

ID=42768604

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201010161388 Expired - Fee Related CN101843668B (en) 2010-04-28 2010-04-28 Chinese medicinal granules for treating femoral head necrosis and preparation method thereof

Country Status (1)

Country Link
CN (1) CN101843668B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104383524A (en) * 2014-11-27 2015-03-04 桂林瑞丰环保微生物应用研究所 Health product for strengthening bone
CN104906374A (en) * 2015-06-05 2015-09-16 鲍少华 Traditional Chinese medicine for treating injury stasis type femoral head necrosis and preparing method
CN107375611A (en) * 2017-08-18 2017-11-24 福建省中医药研究院(福建省青草药开发服务中心) A kind of Chinese medicine composition and preparation method with chest enlarge effect

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1840057A (en) * 2006-01-12 2006-10-04 李保明 Medicine for treating femoral head necrosis and femur neck fracture and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1840057A (en) * 2006-01-12 2006-10-04 李保明 Medicine for treating femoral head necrosis and femur neck fracture and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
《中医正骨》 20080430 章建华等 骨健制剂对激素性股骨头坏死血液流变学的影响 13-14 1-4 第20卷, 第4期 2 *
《中医正骨》 20080531 成立等 骨健口服液治疗股骨头缺血性坏死疗效观察-附136例病例报告 14-16 1-4 第20卷, 第5期 2 *
《浙江中医学院学报》 20050731 章建华等 骨健口服液治疗激素性股骨头坏死60例临床报告 19-20 1-4 第29卷, 第4期 2 *
《辽宁中医药大学学报》 20070331 杨凯 股骨头缺血性坏死中医药治疗进展 54-56 1-4 第9卷, 第2期 2 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104383524A (en) * 2014-11-27 2015-03-04 桂林瑞丰环保微生物应用研究所 Health product for strengthening bone
CN104383524B (en) * 2014-11-27 2016-09-21 桂林瑞丰环保微生物应用研究所 A kind of health product strengthening sclerotin
CN104906374A (en) * 2015-06-05 2015-09-16 鲍少华 Traditional Chinese medicine for treating injury stasis type femoral head necrosis and preparing method
CN107375611A (en) * 2017-08-18 2017-11-24 福建省中医药研究院(福建省青草药开发服务中心) A kind of Chinese medicine composition and preparation method with chest enlarge effect
CN107375611B (en) * 2017-08-18 2021-05-11 福建省中医药科学院 Traditional Chinese medicine composition with breast enlargement effect and preparation method thereof

Also Published As

Publication number Publication date
CN101843668B (en) 2012-07-04

Similar Documents

Publication Publication Date Title
CN100339123C (en) Traditional Chinese medicine liquor and preparation method thereof
CN103656238B (en) A kind of Chinese medicine composition for the treatment of rheumatic osteopathia
CN101347563B (en) Medicament for treating baldness and white hair and preparation method thereof
CN101361923A (en) Traditional Chinese medicine for treating rheumatism
CN103623341A (en) Drug for treating hypertension and cardiovascular and cerebrovascular diseases caused by hypertension
CN104922543A (en) Medicine composite for treating amenorrhea and preparation method thereof
CN101703695A (en) Compound dendrobium candidum blood-nourishing and liver-softening capsule and preparation method thereof
CN1284567C (en) Medicinal liquid for treating osteoporosis and its preparation method
CN103263480B (en) Pharmaceutical composition for treating femoral head necrosis and preparation method thereof
CN101095768B (en) Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age
CN101843668B (en) Chinese medicinal granules for treating femoral head necrosis and preparation method thereof
CN101138597B (en) Traditional Chinese medicine preparation for preventing and controlling osteoporosis and method of preparing the same
CN100421699C (en) Compound Chinese medicinal preparation for treating male sterility
CN106421432A (en) Traditional Chinese medicine for treating aged body deficiency syndrome and delaying senescence
CN1762454A (en) Chinese traditional medicinal composition for treating psoriasis
CN102114070B (en) Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof
CN109602817A (en) A kind for the treatment of is reduced the Chinese medicine composition of caused osteoporosis by estrogen
CN104258359A (en) Traditional Chinese medicine combination for curing pregnancy reaction and preparation method of preparations thereof
CN103536849A (en) Drug for treating pulmonary embolism and preparation method thereof
CN102293923A (en) Application of Tibetan medicinal composition to preparation of medicament for preventing and treating osteoporosis
CN1185970A (en) External use medicine for vitiligo
CN106620475B (en) Traditional Chinese medicine composition for preventing and treating diabetes cognitive impairment and preparation method thereof
CN114522196B (en) Compound traditional Chinese medicine for preventing and treating osteoporosis and preparation method thereof
CN1236804C (en) Making method of capsule for treating hemorrhoid
CN101129706A (en) Traditional Chinese medicine formulated product for treating arteriosclerosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120704

Termination date: 20160428